R&D channel feed

Now a three-time los­er, selume­tinib con­tin­ues to cause headaches as As­traZeneca dumps a failed PhI­II

7 years ago

FDA slaps a hold on Sarep­ta's Duchenne MD study in the wake of stel­lar ear­ly re­sults

7 years ago

Ei­sai, Bio­gen bat­tered by con­tro­ver­sy over PhII Alzheimer's study af­ter post­ing pos­i­tive re­sults

7 years ago

Take­da R&D team rings the block­buster bell with key PhI­II suc­cess in front­line lung can­cer

7 years ago

Mer­ck claims a need­ed win for Keytru­da with in­ter­im OS da­ta in head and neck can­cer

7 years ago

Months af­ter IPO, No­var­tis spin­out resTOR­bio wins on PhI­Ib da­ta — stock soars

7 years ago

This is it? GSK rolls out a buzzy new R&D plan long on as­pi­ra­tions and short on per­for­mance goals

7 years ago
Bioregnum
Opinion

With moth­ers on erec­tile dys­func­tion drug, 11 new­born ba­bies die af­ter tri­al trig­gers lung prob­lems

7 years ago

As Ei­sai, Bio­gen plot a course to ac­cel­er­at­ed ap­provals for Alzheimer’s drug, a mob of skep­tics are wait­ing to de­ci­pher hard num­bers

7 years ago
Pharma

Mar­ket slack­er Cel­gene does some­thing good for a change, look­ing to turn the cor­ner on past mishaps

7 years ago

GSK banks on promis­ing da­ta from its PhI­II Gem­i­ni pro­gram to stare down Gilead on HIV — but there are plen­ty of skep­tics

7 years ago

Top 10 pipeline blowups, set­backs and sna­fus in H1 2018

7 years ago
Special

Lil­ly inks R&D deal with An­i­ma, pay­ing $44M in re­search fund­ing and up­front pay­ments

7 years ago
Pharma

Num­ber 7? Cel­gene part­ner BeiGene joins the crowd with stel­lar PD-1/L1 da­ta from a piv­otal test

7 years ago

Bat­tered and weary, Vi­cal flags for help fol­low­ing its line­up of lemons

7 years ago

In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

7 years ago

Af­ter bil­lion-dol­lar drug deal, pa­tient death and tri­al hold crip­ple Mer­sana's shares

7 years ago

Gilead brings Medicxi’s tiny Gade­ta in­to the cell ther­a­py fold, hunt­ing a way to pick the lock on sol­id tu­mors

7 years ago
Discovery

Go­ing deep­er in­to the ezce­ma game, No­var­tis or­ches­trates $1.1B deal for a Mor­phoSys/Gala­pa­gos drug

7 years ago
Pharma

Roche’s IM­pow­er 132 hits on pro­gres­sion-free sur­vival, but Mer­ck re­mains in con­trol — for now — on front­line lung can­cer

7 years ago

Eli Lil­ly, Pfiz­er cel­e­brate a PhI­II suc­cess for their block­buster pain drug con­tender tanezum­ab -- but ques­tions linger

7 years ago

Roche hands over an­oth­er batch of pos­i­tive PhI­II da­ta on its new flu drug, look­ing for an ear­ly-win­ter launch

7 years ago

J&J de­clares a his­toric suc­cess as In­vokana comes through in PhI­II chron­ic kid­ney dis­ease tri­al

7 years ago

Tak­ing on biode­fense threats, an­tibi­otics mak­er Spero inks $54M in gov­ern­ment deals

7 years ago
Pharma
First page Previous page 266267268269270271272 Next page Last page
A service from the Financial Times